Formulation Development
Provectus Announces Presentation of Initial Results from Phase 1B Trial
Provectus recently announced that data from the company's ongoing Phase 1b/2 study of lysosomal-targeting cancer immunotherapy PV-10 (rose bengal disodium) in combination with KEYTRUDA (pembrolizumab)…
Amarantus Announces Issuance of Chinese Patent
Amarantus Bioscience Holdings, Inc. recently announced that subsidiary MANF Therapeutics has been issued a Chinese patent covering the use of mesencephalic astrocyte-derived neurotrophic factor (MANF)…
Harpoon Therapeutics & AbbVie Announce Licensing & Option Collaboration
Harpoon Therapeutics, Inc. and AbbVie Inc. recently announced an exclusive worldwide option and license transaction for HPN217, Harpoon’s B cell maturation antigen (BCMA)-targeting Tri-specific T…
Zelluna & Glycostem Announce Development, License & Supply Agreement
Zelluna Immunotherapy and Glycostem Therapeutics BV recently announce they have entered into a development, license, and supply agreement. This collaboration will focus on the development…
Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study
Biogen Inc. recently announced the enrollment of the last patient in the global Phase 3 STAR clinical study, which is evaluating the investigational gene therapy…
Protalix BioTherapeutics & Chiesi Farmaceutici Announce Successful Pre-BLA Meeting
Protalix BioTherapeutics, Inc. and its development and commercialization partner, Chiesi Farmaceutici S.p.A. recently announced that they have completed a successful Type B Pre-Biologics License Application (BLA) meeting with the US FDA regarding….
Seelos Therapeutics Receives FDA Fast Track Designation for Intranasal Drug
Seelos Therapeutics, Inc. recently announced the US FDA has granted Fast Track designation to its new, investigational intranasal racemic ketamine program, SLS-002, for the treatment of…..
Cytel Acquires MTEK Sciences, Further Expanding Advanced Real-World Analytics Capabilities
Cytel Inc. recently announced that it has acquired MTEK Sciences to further expand its advanced real-world analytics (RWA) capabilities….
Atlas Nanotech Targets the World’s Largest Consumer Health Products Companies
Costas, Inc. DBA/Atlas Nanotech, (the Company) is currently in discussions to license their proprietary nanotechnology vitamin a (retinol) based crystalline eye drops known under the…
CURE Pharmaceutical Takes First Step to Acquire Coeptis Pharmaceuticals
CURE Pharmaceutical recently announced it purchased a $200,000 convertible promissory note issued by Coeptis Pharmaceuticals, Inc., a biopharmaceutical company engaged in the acquisition, development and…
PromoCell Now Offers In Vitro Disease Models That Could Lead to New Therapies
PromoCell now offers cell disease models covering a wide range of diseases, including diabetes type 1 and 2, respiratory diseases, such as COPD and asthma,…
Centogene Signs Collaboration Agreement With Pfizer
CENTOGENE recently announced a new data access and collaboration agreement with Pfizer Inc. The agreement grants Pfizer access to CENTOGENE’s data repository, which may be…
Aravive & AstraZeneca Announce Initiation of Randomized Phase 1/2 Study
Aravive, Inc. and AstraZeneca recently announced that an investigator-sponsored Phase 1/2 clinical trial of AVB-500, a GAS6/AXL inhibitor, in combination with durvalumab, a PD-L1 inhibitor,…
NervGen Pharma Expands Platform Into Alzheimer's Disease
NervGen Pharma Corp. recently announced a research initiative to advance its proprietary therapeutic technology platform, currently in development for spinal cord injury and multiple sclerosis,…
Flexion Announces Clearance of NDA for Gene Therapy Candidate
Flexion Therapeutics, Inc. recently announced clearance of the company’s Investigational New Drug (IND) application for FX201 in knee osteoarthritis.
Cycle Pharmaceuticals & Catalent Partner to Develop Treatments for Rare Diseases
Cycle Pharmaceuticals Ltd. has recently signed an agreement with Catalent, Inc. to develop innovative formulations targeting rare disease patients.
Ashland Launches New Excipient Solutions for Improved Drug Delivery
Ashland recently announced the launch of three new pharmaceutical solutions, Plasdone S630 Ultra, Benecel XR and XRF, and Viatel bioresorbable polymers. Ashland is expanding its portfolio to meet formulators’ growing needs….
Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials
Menlo Therapeutics Inc. recently announced it has completed enrollment of patients in its two Phase 3 clinical trials evaluating the safety and efficacy of once-daily…
Artelo Biosciences Announces Selection of Clinical Research Organization
Artelo Biosciences, Inc. recently announced it has selected Aptus Clinical Ltd. (Aptus) as its contract research organization (CRO) for the company’s planned Phase 1b/2a randomized,…
Disc Medicine Completes $50-Million Series A Financing, Enters Exclusive License Agreement With AbbVie
Disc Medicine recently announced the completion of a $50-million Series A financing. The company’s novel approach focuses on targeting hepcidin, a key regulator of iron…